Bioxcel therapeutics strengthens cash position to advance serenity at-home pivotal phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia

Topline data expected in second half of 2025 to support potential snda submission for label expansion of igalmi ® in the home setting

BTAI Ratings Summary

BTAI Quant Ranking